{"url_path":"/sec/ipsc/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059824-index.html","accession_number":"0001104659-26-059824","cik":"0001850119","ticker":"IPSC","issuer_name":"Century Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059824-index.html","primary_entity_key":"0001850119","primary_entity_name":"Century Therapeutics, Inc."},"word_count":318,"has_tables":true,"body_markdown":"false\n0001850119\n\n0001850119\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n** **\n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nMay 13, 2026**\n\n \n\n**Century Therapeutics, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**001-40498**\n \n**84-2040295**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n \n(Commission File Number)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**25\nNorth 38th Street**, **11th Floor**\n\n**Philadelphia, Pennsylvania**\n\n \n**19104**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(267) 817-5790**\n\n \n\n**Not Applicable**\n\n(Former name or former address, if changed since\nlast report)\n\n** **\n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.\nbelow):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n \n**Trading Symbol**\n \n**Name\nof Exchange on Which Registered**\n\n**Common Stock, par value $0.0001 per share**\n \n**IPSC**\n \n**Nasdaq Capital Market**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}